Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

ative risk reduction 46 percent; p<0.001)
  • Trend toward lower risk of major bleeding alone: 13 patients, 0.9 percent versus 25 patients,1.8 percent (relative risk reduction 48 percent; p=0.06)
  • A higher rate of acute coronary syndrome (ACS) events was observed in the dabigatran group versus warfarin (13 patients, 0.9 percent versus three patients, 0.2 percent, respectively; p=0.02)
  • RE-SONATE

    • Design: 1,343 patients randomized to dabigatran 150 mg (681 patients) or placebo (662 patients) for six months with extended follow-up to evaluate the long-term risk of recurrence (12 months after completion of study treatment)
    • Efficacy: 92 percent risk reduction for recurrent or fatal VTE with dabigatran versus placebo (three patients, 0.4 percent versus 37 patients, 5.6 percent; p<0.001 for superiority)
    • Safety: the incidence of major bleeding was two patients in the dabigatran group versus zero patients in the placebo group. A higher rate of major or clinically relevant bleeding in the dabigatran group versus no treatment was observed (36 patients, 5.3 percent versus 12 patients, 1.8 percent; p=0.001)

    * Pradaxa® (dabigatran etexilate mesylate) capsules are not approved by the U.S. Food and Drug Administration for the prevention of recurrent VTE or the treatment of acute VTE.

    About Pradaxa® (dabigatran etexilate mesylate) Capsules

    Indications and Usage
    Pradaxa® (dabigatran etexilate mesylate) capsules is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

    IMPORTANT SAFETY INFORMATION ABOUT PRADAXA

    CONTRAINDICATIONS
    PRADAXA is contraindicated in patients with:

    • Active pathological bleeding
    • A known serious hypersensitivity rea
      '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
    2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
    3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
    4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
    5. Shingles Vaccine is Safe, According to New Study
    6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
    7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
    9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
    11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... 27, 2015 Levi & Korsinsky announces it ... OHRP ) concerning possible violations of federal securities ... Company in connection with its study of the drug ... or contact Joseph E. Levi, Esq. ... telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
    (Date:3/27/2015)... MONTREAL , March 27, 2015 /CNW Telbec/ - ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 ... of a working group on the biopharmaceutical industry. However, ... medicines budget. "We commend the government,s intent ... the announcement of measures to promote Quebec,s ...
    (Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today announced it ... South First St. in the Temple Medical and Education District ... of Temple to receive funding for redevelopment. Located ... Health Care System, the new facility will enable THBD to ... life science companies. Temple ...
    Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2
    ... 2011 Samplify Systems, Inc., a leading provider of ... scientific markets, has completed its Series B round of ... fund its rapid growth in its existing markets, and ... the round are Integrated Device Technology, Inc. (Nasdaq: ...
    ... THOUSAND OAKS, Calif., March 4, 2011 Amgen (Nasdaq: ... the acquisition of BioVex Group, Inc., a privately held ... in Abingdon, UK. The acquisition includes OncoVEX(GM-CSF), a novel ... may represent a new approach to treating melanoma and ...
    Cached Medicine Technology:Samplify Systems Completes Series B Funding 2Samplify Systems Completes Series B Funding 3Amgen Completes Acquisition of BioVex 2Amgen Completes Acquisition of BioVex 3Amgen Completes Acquisition of BioVex 4
    (Date:3/28/2015)... 28, 2015 Andrew Hawley of Vintage Rock ... psychedelic concert posters. The Who and the Doors played together ... 2, 1968. According to Hawley, “The Who toured the United ... and college campuses. Perhaps the most famous Who poster was ... and the Doors on August 2, 1968 at the Singer ...
    (Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
    (Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
    (Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
    (Date:3/28/2015)... 28, 2015 Servpro of Paso ... week released a report about the link between mold ... sufferers, and according to recent medical research, may even ... to the Environmental Protection Agency, people with sensitivity to ... in mold may trigger asthma attacks for asthma sufferers. ...
    Breaking Medicine News(10 mins):Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For&nbsp;Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
    ... peers are doing seems to matter, expert surmise, , MONDAY, ... friends really weren,t drinking as much as it might seem, ... , Researchers from Oxford Brookes University in England reviewed 22 ... States. The researchers divided the students into two groups: those ...
    ... NASHVILLE, Tenn., July 20 HealthLeaders-InterStudy, a leading ... the Los Angeles market are struggling to recruit physicians, particularly ... the recent Los Angeles Market Overview , ... to physicians, ranging from $250 to $4,000 a day, to ...
    ... , PITTSBURGH, July 20 Mylan Inc. (Nasdaq: ... million preferred stock issuance, the company has declared its quarterly dividend of ... a liquidation preference of $1,000.00 per share) payable on August 17, 2009, ... , , Mylan Inc., which provides products ...
    ... , SEATTLE, July 20 Group Health ... 15 quality measures in the Puget Sound Health Alliance Community ... any of the other nine medical groups in the Puget Sound region ... Health received no "below regional average" scores. , , ...
    ... , , CLEVELAND, July 20 ... global eClinical solutions for the clinical trials industry, announced today that ... DATATRAK CRO Connect Program(TM). ARA will utilize DATATRAK eClinical(TM) to ... paper and EDC clients. , , ...
    ... , , ... 20 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today announced that ... drug for the treatment of obesity, met their co-primary endpoints. The results ... besity R esearch, or COR, program of more than 4,500 ...
    Cached Medicine News:Health News:Perception May Affect Drinking by College Students 2Health News:l.a. Hospitals Struggle for Emergency Room Care, Pay Physicians High Fees for On-Call Coverage 2Health News:Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 3Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 2Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 5Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 6Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 7Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 8Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 9
    ... ,The S/5 Critical Care Monitor is a multiparameter ... varying needs of critical care. The S/5 Critical ... options, display and mounting options, remote control and ... set-up to help meet your needs. The new ...
    ... for size., ,The Datex-Ohmeda S/5 Light Monitor ... in anesthesia and critical care areas, in emergency ... transport. As part of the Datex-Ohmeda S/5 family, ... user interface and design shared by all S/5 ...
    ... to use., ,The S/5 Compact Critical ... ideally suited for medium care monitoring. The ... Datex-Ohmeda supplies and accessories., ,The S/5 ... user interface and features as the S/5 ...
    ... need in day surgery and post anesthesia care ... Anesthesia Monitor is a high performance monitor designed ... anesthesia care and induction rooms. It offers the ... parameters and advanced airway gas monitoring. When paired ...
    Medicine Products: